MetLife, Inc. filings document the regulatory record of a Delaware financial services company with NYSE-listed common stock and preferred securities, including depositary shares tied to Series E and Series F preferred stock. Recent Form 8-K reports furnish earnings releases, quarterly financial supplements, total assets under management fact sheets and Regulation FD disclosures related to variable investment income.
The filings also cover capital-structure actions such as subordinated debenture issuance and preferred stock dividend declarations. Proxy materials describe board composition, committee assignments, executive compensation and shareholder voting matters, while material-event reports record governance changes and other corporate disclosures.
HUBBARD ROBERT GLENN reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Robert Glenn Hubbard received a grant of 1,248 shares of common stock valued at $71.17 per share as part of non-management director compensation. This award reflects retainer fees that are paid in MetLife stock rather than cash.
The director elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the shares are credited rather than immediately delivered. Following this grant, he holds 105,878 shares of MetLife common stock directly.
MORRISON DENISE M reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Denise M. Morrison received a grant of 721 shares of MetLife common stock on 2026-04-01 as part of non-management director compensation arrangements. The shares were awarded at $0.00 per share, reflecting stock-based fees rather than a market purchase.
After this award, Morrison directly holds 34,711 shares of MetLife common stock. A portion of MetLife’s non-management director retainer fees is paid in common stock, so this transaction represents routine equity compensation rather than an open-market trade.
Mumenthaler Christian Stephane reported acquisition or exercise transactions in this Form 4 filing.
METLIFE INC director Christian Stephane Mumenthaler received an equity grant of MetLife common stock as part of his board compensation. On this Form 4, he was awarded 721 shares of common stock at $71.17 per share, increasing his directly reported holdings to 2,846 shares. The footnote explains that MetLife pays a portion of non-management director retainer fees in common stock and that he elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors, so the compensation is taken in stock units rather than immediate cash.
Hay Laura J reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Laura J. Hay received a grant of 721 shares of common stock valued at $71.17 per share as part of non-management director compensation. After this award on April 1, 2026, she directly holds 5,692 shares. The footnote explains that MetLife pays a portion of non-management director retainer fees in common stock, and Hay elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This is a routine, compensation-related share award rather than an open-market purchase.
MCKENZIE DIANA reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Diana McKenzie received a grant of 721 shares of common stock, valued at $71.17 per share, as part of non-management director retainer fees. Following this award, she directly holds 24,472 shares. She elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Glaser Daniel S reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Daniel S. Glaser received an equity award of 721 shares of common stock, valued at $71.17 per share. The award represents a portion of his non-management director retainer fees paid in stock. He elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors.
Following this grant, Glaser directly holds 2,101 shares of MetLife common stock. In addition, 198 shares are held indirectly in a GRAT, reflecting an estate-planning vehicle associated with his holdings.
GUTIERREZ CARLOS M reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Carlos M. Gutierrez received a grant of 721 shares of MetLife common stock on April 1, 2026. The shares were awarded at no cash cost as part of non-management director retainer fees paid in stock. Following this award, he directly holds 25,745 common shares and indirectly holds 18,807 additional shares through the Carlos M. Gutierrez Trust.
WEINBERGER MARK A reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Mark A. Weinberger received 721 shares of MetLife common stock as a grant tied to his non-management director retainer fees. The shares were awarded at no cash cost per share and increased his direct holdings to 18,801 shares of MetLife common stock.
Johnson Jeh C. reported acquisition or exercise transactions in this Form 4 filing.
MetLife Inc. director Jeh C. Johnson received 721 shares of common stock as a compensation award. The grant was valued at $71.17 per share and increased his directly held position to 8,850 shares.
A footnote explains that a portion of non-management director retainer fees is paid in MetLife common stock, and Johnson elected to defer receipt of these shares under the MetLife Deferred Compensation Plan for Non-Management Directors. This indicates the transaction is a routine equity-based board compensation event rather than an open-market purchase or sale.
MetLife submitted a Form 144 reporting proposed sales of Common Stock by affiliated accounts. The filing lists specific planned transactions and several sales completed in the prior three months, with per-transaction share counts and associated dollar amounts shown for accounts including MetLife 401k Plan Trust and Separate Account SPI.